前列腺癌患者基于基准标记与基于骨性标志的图像引导放疗疗效比较
该回顾性研究纳入2008至2011年间接受kV-kV图像引导放疗的180例前列腺癌患者,比较基于骨性标志(BB组89例)与基于基准标记(FB组91例)两种图像引导方式的临床结局。两组急性及晚期毒性、5年生化进展无显著差异,但中危组5年总生存FB组93% vs BB组75%(p=0.06),作者认为中危患者可能从基准标记引导中获益最多。
要点
- 两组急性G2/G3泌尿及胃肠道毒性发生率相似。
- 5年晚期≥G2泌尿毒性两组均为12%(p=0.98),≥G2胃肠道毒性BB组19% vs FB组15%(p=0.55)。
- 中危组5年总生存FB组93% vs BB组75%(p=0.06),作者认为中危患者可能从基准标记引导中获益最多。
核心结论
- 比较基于骨性标志与基于基准标记的图像引导技术,未观察到临床结局或晚期毒性的差异;但中危前列腺癌患者可能是从基准标记引导IGRT中获益最多的人群。
研究设计与样本
- 回顾性研究,纳入2008至2011年间接受kV-kV图像引导放疗的180例前列腺癌患者,其中89例对准骨盆骨(BB组),91例对准植入前列腺的基准标记(FB组)。
- 患者接受总剂量76 Gy,分38次照射。
- 采用Cox回归模型评估临床及治疗相关参数对总生存、生化进展和无进展生存的影响;急性和晚期毒性依据RTOG/EORTC标准评估;性功能采用QLQ PR-25(EORTC QLQ量表)评估;并评估患者从模拟定位时起的每日摆位差异。
主要发现
- 急性G2/G3泌尿毒性:BB组G2 34例、G3 5例,FB组G2 40例、G3 2例,两组相似。
- 急性G2/G3胃肠道毒性:BB组G2 24例、G3 1例,FB组G2 18例、G3 1例。
- 5年晚期≥G2泌尿毒性发生率两组均为12%(p=0.98);≥G2胃肠道毒性BB组19% vs FB组15%(p=0.55)。
- 5年无进展生存率BB组87% vs FB组81%(p=0.15);5年总生存率BB组80% vs FB组91%(p=0.20)。
- 中危组5年总生存FB组93% vs BB组75%(p=0.06)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To compare the clinical outcome in prostate cancer patients treated with radiotherapy using two forms of image guidance: bone-based (BB) or fiducial-based (FB). MATERIAL AND METHODS: This retrospective study consisted of 180 patients treated with kV-kV image-guided radiotherapy (IGRT) between the years 2008 and 2011. A total of 89 patients were aligned to pelvic bone (Group BB) and 91 patients to the fiducial implanted into prostate for image guidance (Group FB). Patients were treated to a total dose of 76 Gy in 38 fractions. The Cox Regression Model was used to evaluate the influence of clinical and treatment-related parameters on overall survival, biochemical progression and progression-free survival. Acute and late toxicity were evaluated based on the RTOG/EORTC criteria. Sexual function was assessed with QLQ PR-25 (EORTC QLQ forms). An assessment of the differences in patient daily set-up from the time of simulation was performed. RESULTS: The incidence of acute G2/G3 genitourinary (GU) and gastrointestinal (GI) toxicity was similar between groups. In the BB group, 34 patients had G2 and 5 had G3 GU acute toxicity - compared to 40 patients with G2 and 2 with G3 in the FB group. G2 and G3 GI acute toxicity was observed respectively in 24 patients and in 1 patient in the BB group compared to 18 patients with G2 and 1 patient with G3 toxicity in the FB group. The five-year incidence of late ≥G2 GU toxicity was 12% in both groups (p = 0.98) and ≥ G2 GI toxicity 19% (BB) vs 15% (FB, p = 0.55), respectively. The five-year progression-free survival rate was 87% in BB and 81% in the FB Group (p = 0.15). The 5-year Overall Survival rate (OS) was 80% (BB) vs 91% % (FB, p = 0.20), but the difference was most pronounced in the intermediate-risk group: 5-year OS of 93% (FB) and 75% (BB), respectively (p = 0.06). No significant changes were observed in sexual or erectile functioning as compared to that specified at the beginning of radiotherapy and between the FB and BB Groups. CONCLUSION: When comparing bone-based to fiducial-based techniques, no differences in clinical outcomes or late toxicity were seen in this population. However, intermediate risk prostate cancer patients are those who might benefit most from implementation of fiducial-based IGRT.
引用
- Napieralska A, Majewski W, Kulik R, et al. A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients. Radiat Oncol. 2018. PMID: 30482212. doi:10.1186/s13014-018-1171-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。